Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muscadine Plus in Men With Prostate Cancer
NCT01317199Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2011
- Primary completion
- Nov 2015
- Modality
- Dietary Supplement, PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Muscadine Grape Skin Extract in prostate cancer (PCa) (4 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 7 months and Prostate Specific Antigen Doubling Time at 12 months. Started Jul 2011; status: completed.
02
Drugs
Muscadine Grape Skin Extract
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01317199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01317199.